We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
(+21%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
32.16%
Top 10 Holdings %
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Realty Income
O
|
+$931K |
| 2 |
SK Telecom
SKM
|
+$871K |
| 3 |
Moderna
MRNA
|
+$825K |
| 4 |
ConocoPhillips
COP
|
+$786K |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$785K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agnico Eagle Mines
AEM
|
+$1.83M |
| 2 |
BPMP
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
|
+$1.76M |
| 3 |
The Mosaic Company
MOS
|
+$928K |
| 4 |
STR
Sitio Royalties
STR
|
+$559K |
| 5 |
Gold Fields
GFI
|
+$512K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.55% |
| 2 | Healthcare | 17.07% |
| 3 | Materials | 11.98% |
| 4 | Financials | 11.43% |
| 5 | Energy | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Exelixis
EXEL
$14.1B
| $273K | 0.1% |
13,133
-8,747
| -40% | -$180K |
|
|
MRCC
277
DELISTED
Monroe Capital Corp
MRCC
| $272K | 0.1% |
30,172
+789
| +3% | +$7.89K |
|
278
Kiniksa Pharmaceuticals
KNSA
$4.96B
| $271K | 0.1% |
27,992
-2,029
| -7% | -$18.9K |
|
|
APLS
279
DELISTED
Apellis Pharmaceuticals
APLS
| $270K | 0.1% |
5,970
-2,755
| -32% | -$126K |
|
280
Nektar Therapeutics
NKTR
$2.37B
| $270K | 0.1% |
4,731
+2,775
| +142% | +$175K |
|
281
Sarepta Therapeutics
SRPT
$1.73B
| $270K | 0.1% |
3,596
-749
| -17% | -$55.1K |
|
282
BioMarin Pharmaceuticals
BMRN
$11.7B
| $269K | 0.1% |
3,246
-1,240
| -28% | -$98.7K |
|
283
Oxford Square Capital
OXSQ
$154M
| $269K | 0.1% |
73,914
-5,407
| -7% | -$21.5K |
|
284
Vanda Pharmaceuticals
VNDA
$318M
| $268K | 0.1% |
24,569
+1,234
| +5% | +$12.8K |
|
285
Incyte
INCY
$23.8B
| $266K | 0.1% |
3,506
-1,917
| -35% | -$146K |
|
286
Ascendis Pharma A/S
ASND
$16.7B
| $265K | 0.1% |
2,856
+134
| +5% | +$12.6K |
|
287
Insmed
INSM
$23B
| $263K | 0.1% |
13,344
-525
| -4% | -$11K |
|
288
BioCryst Pharmaceuticals
BCRX
$2.49B
| $260K | 0.1% |
24,556
-7,986
| -25% | -$82.4K |
|
289
Stellus Capital Investment Corp
SCM
$207M
| $260K | 0.1% |
23,403
-22,869
| -49% | -$295K |
|
290
BioNTech
BNTX
$23.2B
| $257K | 0.1% |
1,721
+377
| +28% | +$57.6K |
|
|
BPMC
291
DELISTED
Blueprint Medicines
BPMC
| $257K | 0.1% |
5,089
+1,327
| +35% | +$77.7K |
|
292
Ionis Pharmaceuticals
IONS
$9.26B
| $256K | 0.09% |
6,925
-5,371
| -44% | -$203K |
|
|
CTIC
293
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $255K | 0.09% |
+42,735
| New | +$219K |
|
294
Harmony Biosciences
HRMY
$2.08B
| $254K | 0.09% |
5,218
-4,468
| -46% | -$201K |
|
295
Alnylam Pharmaceuticals
ALNY
$37.7B
| $253K | 0.09% |
1,738
-265
| -13% | -$37.6K |
|
296
Roivant Sciences
ROIV
$25B
| $253K | 0.09% |
62,129
+43,583
| +235% | +$173K |
|
297
United Therapeutics
UTHR
$26.5B
| $250K | 0.09% |
1,063
-855
| -45% | -$174K |
|
298
Gilead Sciences
GILD
$164B
| $248K | 0.09% |
4,015
-1,259
| -24% | -$77.9K |
|
299
Neurocrine Biosciences
NBIX
$17.8B
| $248K | 0.09% |
2,544
-1,953
| -43% | -$180K |
|
300
Aurinia Pharmaceuticals
AUPH
$1.97B
| $247K | 0.09% |
24,556
+3,903
| +19% | +$43.6K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.
Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.
By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.
- Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
- Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
- Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
- Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
- Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
- Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
- Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.
Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.